Submit a Letter to the Editor for:
Nathalie Bendriss-Vermare, Clarisse Barthélémy, Isabelle Durand, Corine Bruand, Colette Dezutter-Dambuyant, Nathalie Moulian, Sonia Berrih-Aknin, Christophe Caux, Giorgio Trinchieri, Francine Brière
J Clin Invest. 2001;
107(7):835
doi:10.1172/JCI11734
Abstract |
Full text
|
PDF
T
hree distinct dendritic cell (DC) subsets capable of stimulating allogeneic naive T cells were isolated from human thymus. The most abundant subset was represented by plasmacytoid DCs (pDCs), which secreted high amounts of IFN-α upon stimulation with inactivated influenza virus and thus likely correspond to the recently identified peripheral blood natural IFN-α/β–producing cells (IPCs). Like those latter cells, thymic pDCs had distinctive phenotypic features (i.e., Lin–, HLA-DRint, IL-3Rαhi, CD45RAhi, CD11c–, CD13–, and CD33lo) and developed into mature DCs upon culture in IL-3 and CD40L. Of the two other DC subsets, one displayed a phenotype of immature myeloid DCs (imDCs) (HLA-DRint, CD11c+, CD13+, CD33+), and the other represented HLA-DRhi CD11c+ mature DCs (mDCs). Since they also expressed DC-LAMP, these mDCs appear to correspond to interdigitating dendritic cells (IDCs). Thymic pDCs, but not myeloid imDCs, strongly expressed lymphoid-specific transcripts such as pre-Tα, λ-like, and Spi-B, thereby suggesting a possible lymphoid origin. The detection of Spi-B mRNA, not only upon in vitro maturation of pDCs, but also in freshly purified IDCs, suggests that in vivo pDCs may differentiate into IDCs.
Guidelines:
The Editorial Board will only consider letters that we deem relevant and of interest to our readers. We will not post data that have not been subjected to peer review, nor will we post letters that are essentially a reiteration of another letter. All accepted letters will be posted on our website within one week of acceptance. The Editors reserve the right to edit any letter for length, content, and clarity. Authors of all accepted letters will be asked to preview any changes. Authors will be notified by e-mail if their letters were not accepted. As this is a final decision, no appeals will be considered.
Specific requirements: All letters must be 400 words or fewer. You may enter the letter as plain text or HTML, if you wish. The author's name and e-mail address are required, and will be posted with the letter. All possible conflicts of interest must be noted, even if they are not posted. If you wish to include a figure (keep in mind that non-peer-reviewed data will not be posted), please contact the editor directly at editors@the-jci.org.
